<DOC>
	<DOCNO>NCT01026038</DOCNO>
	<brief_summary>This open-label study ( study doctor participant know drug vaccine administer ) child previously receive 4-dose series pneumococcal conjugate vaccine ( PnC ) infancy Study 6096A1-008-EU ( NCT00366678 ) . In study , participant receive additional dose 13-valent pneumococcal conjugate vaccine . The purpose study evaluate persistence , , antibody response measure remain pneumococcal antibody since previous study . This study also evaluate safety immunogenicity 13-valent pneumococcal conjugate vaccine administer least 24 month last dose pneumococcal conjugate vaccine .</brief_summary>
	<brief_title>Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine ( 13vPnC ) 24 Months After Toddler Dose .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy subject least 3 year age , receive 4 assigned dos pneumococcal conjugate vaccine complete Study 6096A1008EU ( NCT00366678 ) least 24 month Vaccination license investigational pneumococcal vaccine since completion Study 6096A1008EU ( NCT00366678 ) . History cultureproven invasive disease cause S pneumoniae since completion Study 6096A1008EU ( NCT00366678 ) . Previous anaphylactic reaction vaccine vaccinerelated component . Contraindication vaccination</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pneumococcal vaccine 13-valent</keyword>
</DOC>